Published in
American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(36), p. TPS9605-TPS9605
DOI: 10.1200/jco.2018.36.15_suppl.tps9605
Links
Tools
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372.
Journal article published in 2018 by
Shailender Bhatia,
Andrew Scott Brohl,
Isaac Brownell,
Sunandana Chandra,
Sumia Dakhil,
Marc S. Ernstoff,
Leslie Anne Fecher,
Ted Gooley,
Glenn J. Hanna,
Reina Hibbert,
Ciara Marie Kelly,
Samantha M. Kiriluk,
Paul Nghiem 
,
Vivian Nguyen,
Nichole Pelz
and other authors.
,
Vivian Nguyen,
Nichole Pelz
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 